NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

Rhea-AI Summary

NervGen (NASDAQ:NGEN) will ring the Nasdaq closing bell on January 22, 2026 in New York City to mark its recent Nasdaq listing. Adam Rogers, MD, Chairman and Interim CEO, will be joined by management, board members, advisors and guests. The ceremony broadcast begins at 3:45 pm ET and will be livestreamed from the Nasdaq MarketSite Tower and available on Nasdaq’s X and Facebook pages. The event highlights NervGen’s focus on developing neuroreparative therapeutics for spinal cord injury.

Key Figures

Nasdaq closing bell date: January 22, 2026 Current price: $5.63 Daily price change: 2.93% +4 more

7 metrics

Nasdaq closing bell date January 22, 2026 Scheduled ceremony at Nasdaq MarketSite

Current price $5.63 Pre-news market context

Daily price change 2.93% Change over prior 24 hours before news

52-week high $6.30 Pre-news trading range context

52-week low $5.10 Pre-news trading range context

Market cap $445,966,454 Pre-news equity valuation

Broadcast time 3:45 pm ET Start of Nasdaq closing bell livestream

Market Reality Check

Price: $5.84 Vol: Volume 125,608 is below 2...

low vol

$5.84 Last Close

Volume Volume 125,608 is below 20-day average of 239,366 (relative volume 0.52). low

Technical Trading around the 200-day MA at 5.63, close to the long-term trend level.

Peers on Argus

No peers with momentum data were provided, so the 2.93% move appears stock-speci...

No peers with momentum data were provided, so the 2.93% move appears stock-specific rather than sector-driven.

Market Pulse Summary

This announcement highlights NervGen’s recent Nasdaq listing and the upcoming closing bell ceremony ...

Analysis

This announcement highlights NervGen’s recent Nasdaq listing and the upcoming closing bell ceremony on January 22, 2026, reinforcing its visibility as a clinical-stage neuroreparative company focused on spinal cord injury. With shares around the 200-day MA at 5.63 and a 52-week range of $5.10–$6.30, investors may watch future clinical updates, capital markets activity, and listing-related developments for more substantive catalysts.

Key Terms

nasdaq, closing bell, spinal cord injury, neurotraumatic, +1 more

5 terms

nasdaq financial

"NervGen Pharma Corp. … (Nasdaq: NGEN), a clinical-stage biopharmaceutical company…"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

closing bell financial

"announced that the Company will ring the closing bell at the Nasdaq Stock Market…"

The closing bell is the signal that ends a stock exchange’s regular trading day and marks the moment when final, official prices are recorded for listed securities. Like a shop’s closing time that fixes the day’s sales totals, it matters to investors because those end-of-day prices are used to value portfolios, measure performance, settle transactions, and serve as the reference point for news, pricing benchmarks and time-sensitive orders.

spinal cord injury medical

"therapeutics for spinal cord injury (SCI) and other neurotraumatic…"

Damage to the bundle of nerves that runs down the middle of the back and carries messages between the brain and the body; like a cut or crush to an electrical cable that disrupts signals to limbs and organs. It matters to investors because the severity and permanence of the damage drive demand for medical devices, drugs, rehabilitation services and long-term care, shaping the commercial size, regulatory hurdles and revenue timelines for companies developing treatments.

neurotraumatic medical

"neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic…"

Neurotraumatic describes damage to the nervous system — especially the brain or spinal cord — caused by an external injury, such as a blow, fall, or accident. Think of the nervous system as a complex wiring harness: a neurotraumatic event is like a major short-circuit or cut that can disrupt signals and function. Investors care because neurotraumatic conditions drive demand for treatments, devices, diagnostics and long-term care, influence regulatory approval paths and reimbursement, and can materially affect the prospects of healthcare companies.

neuroreparative medical

"developing first-in-class neuroreparative therapeutics for spinal cord injury…"

Neuroreparative describes treatments or technologies designed to restore or repair damaged nerve tissue, pathways, or brain cells after injury or disease. Think of it like fixing the wiring in a house so signals travel again; successful neuroreparative approaches can improve function and reduce long-term care needs. For investors, progress or setbacks in this area influence the commercial potential, regulatory risk, and valuation of companies developing those therapies.

AI-generated analysis. Not financial advice.

VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company will ring the closing bell at the Nasdaq Stock Market (Nasdaq) on Thursday, January 22, 2026 in New York City.

Adam Rogers, MD, Chairman and Interim Chief Executive Officer will be joined by members of the NervGen management team, Board of Directors, advisors, and other guests.

“We are honored to participate in the Nasdaq closing bell ceremony and highlight NervGen’s mission to transform the lives of individuals living with spinal cord injury by enabling the nervous system to repair itself,” said Adam Rogers, MD, Interim Chief Executive Officer of NervGen Pharma. “Becoming a Nasdaq-listed company represents a significant milestone in the growth and evolution of NervGen. This latest accomplishment was made possible through the unwavering support of our shareholders, physician and scientific collaborators, advocacy partners, the individuals and families who have placed their trust in NervGen by participating in our clinical research, and our dedicated management team and advisors.”

The broadcast will begin at 3:45 pm ET and will be livestreamed from the Nasdaq MarketSite Tower in New York City and available on Nasdaq’s X and Facebook pages.

About NervGen Pharma
NervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI between 1 to 10 years post-injury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence, and quality of life. Enrollment of individuals with subacute SCI in the Phase 1b/2a CONNECT SCI Study is ongoing, alongside preparation for a Phase 3 clinical trial in chronic SCI. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.

Contacts
Huitt Tracey, Investors
htracey@nervgen.com
604.537.2094

David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310

Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note and Forward Looking-Statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking statements”). Such forward-looking statements herein include but are not limited to, the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “trend”, “indication”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the expected benefits from the Nasdaq listing; NVG-291’s potential to become the first approved pharmacologic therapy for SCI; the Company’s plans for future regulatory meetings; the Company’s potentially best-in-class candidate, NVG-291; the potential broad therapeutic applications of NVG-291; the future growth of the Company; the Company’s mission to transform the lives of individuals living with spinal cord injury; the Company’s pursuit to revolutionize the treatment paradigm for neurotraumatic conditions with significant unmet medical need; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and final results from our clinical trials of NVG-291 in individuals with spinal cord injury; and the creation of neuroreparative therapeutics to enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: its ability to obtain future funding on favorable terms, if at all; the accuracy of its financial projections; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Many factors could cause the Company’s actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company’s most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen’s profile on SEDAR+ at www.sedarplus.ca and in NervGen’s Form F-10/A filed on EDGAR at www.edgar.com. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

FAQ

When will NervGen (NGEN) ring the Nasdaq closing bell?

NervGen will ring the Nasdaq closing bell on January 22, 2026.

What time will the NervGen Nasdaq closing bell broadcast start on January 22, 2026?

The broadcast will begin at 3:45 pm ET from the Nasdaq MarketSite Tower.

Who will represent NervGen (NGEN) at the Nasdaq closing bell on January 22, 2026?

Adam Rogers, MD, Chairman and Interim CEO, will be joined by NervGen’s management team, board members, advisors and guests.

Where can investors watch NervGen’s (NGEN) Nasdaq closing bell livestream?

The livestream will be available from the Nasdaq MarketSite Tower and on Nasdaq’s X and Facebook pages.

What does NervGen (NGEN) focus on as a Nasdaq-listed company?

NervGen is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurologic conditions.